

obese patients, even in the high-risk older population. Quality of life might also improve considerably through amelioration of comorbid conditions.

**Original article** Perry CD *et al.* (2008) Survival and changes in comorbidities after bariatric surgery. *Ann Surg* **247**: 21–27

### Plasma albumin mRNA levels might predict post-transplant recurrence of HCC

Post-transplant recurrence of hepatocellular carcinoma (HCC) is common, despite routine use of patient-selection criteria based on pretransplantation radiological findings. HCC recurrence in the liver graft is probably caused by cancer cells circulating in the blood, and levels of cancer-derived nucleic acids in plasma are thought to reflect this circulating tumor-cell burden.

Cheung and colleagues analyzed prospectively collected data from 72 patients who underwent liver transplantation for HCC at Queen Mary Hospital, Hong Kong, between 1997 and 2005. They extracted RNA from plasma samples obtained from each patient immediately before surgery, as well as from 10 healthy control individuals and 10 non-HCC liver-transplant recipients. Perhaps surprisingly, albumin messenger RNA (mRNA) levels (but not albumin protein mRNA levels) were significantly associated with post-transplant HCC recurrence ( $P=0.029$ ). The researchers calculated that the ability of preoperative plasma albumin mRNA levels to predict post-transplant HCC recurrence was superior to that of preoperative radiological assessments of tumor size and number, and comparable to that of pathological findings of vascular invasion (overall accuracy 71% for plasma albumin mRNA, compared with 74% for vascular invasion).

The authors note that preoperative assessments of vascular invasion require tumor biopsy, which is a risky procedure. By contrast, plasma albumin mRNA levels are simple and easy to measure. The authors have initiated a multicenter, prospective study in a large group of patients to evaluate their findings further.

**Original article** Cheung ST *et al.* (2008) Albumin mRNA in plasma predicts post-transplant recurrence of patients with hepatocellular carcinoma. *Transplantation* **85**: 81–87

### Patients misperceive the risks and benefits of infliximab therapy for IBD

Infliximab is a chimeric, monoclonal antibody to tumor necrosis factor; this therapy induces or maintains remission of Crohn's disease and ulcerative colitis in ~60% of cases, even if other treatments have failed. Serious adverse effects of infliximab therapy are rare, but include lymphoma and life-threatening infections.

Siegel and colleagues analyzed 165 completed questionnaires that evaluated perceived risks and benefits of infliximab therapy. Respondents were patients, or parents of patients, with IBD who attended patient-education symposia in Boston, MA and Chicago, IL. Respondents overestimated the benefits of infliximab (59% expected a remission rate >50%, and 18% expected a remission rate >70%, at 1 year). They also underestimated its risks: 37% denied a link between infliximab and lymphoma, and 67% thought that infliximab conferred a lymphoma risk less than double that of the general population (the observed risk is ~20-fold that of the general population). When presented with a hypothetical new therapy for IBD that had a risk profile corresponding to that of infliximab, 64% of respondents said they would refuse such treatment, even though one-third of this group were currently taking or had taken infliximab. Parents of patients were less optimistic than patients with regard to both risks and benefits of infliximab therapy.

Many patients with IBD could be taking medications that do not align with their risk–benefit preferences, say Siegel and colleagues. They urge physicians to communicate more effectively with their patients.

**Original article** Siegel CA *et al.* (2008) Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. *Inflamm Bowel Dis* **14**: 1–6

### Cannabis use is a risk factor for fibrosis in patients with chronic HCV infection

HCV-related cirrhosis and liver cancer rates are predicted to increase in the US in the next 10 years. Several risk factors—notably male sex, increased duration of HCV infection, older age at initial infection, heavy alcohol intake and